Amicus Therapeutics Inc

Amicus Therapeutics — Q3 2025 Earnings Presentation

26 slides from Amicus Therapeutics's earnings presentation, Nov 4, 2025

  1. Slide 1: Q3 2025 Results Conference Call & Webcast

    AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Q3 2025 Results Conference Call & Webcast November 4, 2025

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the prospects and timing of the potential regulatory and pricing approval of our products, commercialization plans, manufacturin

  3. Slide 3: A Rare Company

    A Rare Company 3 1 At CER: Constant Exchange Rates $169M Q3 2025 Total Revenue (+17% Growth)1 $1B+ Total Revenue Expected in FY 2028 First Oral Precision Medicine for Fabry Disease 10-15% FY 2025 Galafold Revenue Growth1 Expanded Portfolio with U.S. Licensing of DMX-200 Phase 3 Program Leverageable

  4. Slide 4: Galafold (migalastat) Continued Growth

    4 Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease

  5. Slide 5: Only approved oral treatment in Fabry disease

    5 Only approved oral treatment in Fabry disease and standard of care for amenable patients 2025 Galafold Success (as of September 30, 2025) Galafold is indicated for adults with a confirmed diagnosis of Fabry disease and an amenable variant. The most common adverse reactions reported with Galafold (

  6. Slide 6: Galafold Performance

    6 FY23 FY24 FY25 $388M $458M Quarterly patient starts remain strong: +13% growth YoY in Q3 2025 Highest demand quarter in Q3 2025 and best number of starts YTD since launch Global mix of naïve (~65%) and switch (~35%) patients2 Expanding market through uptake in naïve population as well as label and

  7. Slide 7: Fabry Market: Significant Remaining Unmet Need

    7 Fabry Market: Significant Remaining Unmet Need 7 Based on publicly reported sales of Fabry therapies 1Applying incidence of multiple newborn screening studies to population estimates in commercial markets: Burton 2017 J Pediatr 2017;190:130-5 ; Mechtler et al., The Lancet, 2011 Dec.; Hwu et al., H

  8. Slide 8: New FINDING FABRY website & campaign now live

    8 New FINDING FABRY website & campaign now live New FINDING FABRY Initiative in the U.S. https://findingfabry.com/

  9. Slide 9: Pombiliti + Opfolda

    9 Pombiliti® (cipaglucosidase alfa-atga) Opfolda® (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease +

  10. Slide 10: Pombiliti + Opfolda Performance

    10 FY23 FY24 FY25 Pombiliti + Opfolda Performance Q3 2025 Pombiliti + Opfolda reported revenue of $30.7M (+42% at CER) Q1 $11M Q3 $21M Q4 $22M 1 CER: Constant Exchange Rates 2 Real-World Evidence $70.2M +50-65%1 Q2 $16M Q1 $21M Strong Q3 sales growth YoY – Increasing depth and breadth of prescribers

  11. Slide 11: Significant progress expanding access to Pombiliti + Opfolda in 2025

    11 Significant progress made towards expanding access to Pombiliti + Opfolda in 2025 Pombiliti + Opfolda Expansion Approved in Australia and Canada in Q1 2025 Approved in Japan in June 2025 AUSTRALIA CANADA JAPAN Regulatory Reimbursement Now reimbursed in 15 countries with 10 countries added in 2025

  12. Slide 12: Growing body of evidence supporting Pombiliti + Opfolda differentiation

    12 Growing number of abstracts, manuscripts, and case studies supporting Pombiliti + Opfolda differentiation Pombiliti + Opfolda Body of Evidence Case Studies & Real-World Reports Mechanistic & Translational Insights Long-term Phase 1/2 open-label safety and efficacy study (ATB200-02) 104-week Phase

  13. Slide 13: Emerging Pombiliti + Opfolda Real-World Evidence

    13 Real-world data recently presented by independent researchers Emerging Pombiliti + Opfolda Real-World Evidence cipaglucosidase alfa+ miglustat vs. alglucosidase alfa avalglucosidase alfa vs. alglucosidase alfa 6MWD Significant increase Non-significant decrease 10MWT Significant decrease (faster)

  14. Slide 14: DMX-200 for FSGS

    14 DMX-200 Potential first-in-class investigational small molecule for the treatment of FSGS in the U.S.

  15. Slide 15: FSGS is a rare disease leading to irreversible kidney damage

    15 Irreversible scarring leads to permanent kidney damage and eventual end-stage renal failure1 Symptoms include proteinuria, edema, high cholesterol and blood pressure, low albumin levels Average time from diagnosis to onset of complete kidney failure is typically five to ten years2 FSGS kidney dam

  16. Slide 16: DMX-200 Clinical and Regulatory Progress

    16 MOA Precision therapy to disrupt the pathogenic monocyte-driven inflammatory feedback loop in the kidney of patients with FSGS Phase 2 Positive efficacy signals and well-tolerated across studies (n=80), including impacts on proteinuria and inflammation in FSGS study ACTION3 Phase 3 Enrollment wel

  17. Slide 17: Corporate Outlook

    17 Corporate Outlook Delivering on our mission for patients and shareholders

  18. Slide 18: Q3 2025 Select Financial Results

    18 Q3 2025 Select Financial Results Q3’25 YTD’25 (in thousands, except per share data) Sep. 30, 2025 Sep. 30, 2024 Sep. 30, 2025 Sep. 30, 2024 Net product sales $ 169,061 $ 141,517 $ 448,998 $ 378,589 Cost of goods sold 19,467 13,279 46,382 38,107 GAAP operating expenses 115,325 106,579 385,773 331,

  19. Slide 19: FY 2025 Financial Guidance Reiterated

    19 FY 2025 Financial Guidance Reiterated FY 2025 Financial Guidance1 Total Revenue Growth1 15% to 22% Galafold Revenue Growth1 10% to 15% Pombiliti + Opfolda Revenue Growth1 50% to 65% Gross Margin Mid 80% Non-GAAP Operating Expense $380M to $400M2 GAAP Net Income Positive during H2 2025 1 Full-Year

  20. Slide 20: 2025 Strategic Priorities

    20 1 CER: Constant Exchange Rates 2025 Strategic Priorities Deliver total revenue growth of 15-22% at CER1 Double-digit Galafold® revenue growth of 10-15% at CER1 Pombiliti®+ Opfolda® revenue growth of 50-65% at CER1 Advance ongoing studies in Fabry, Pompe and FSGS Deliver positive GAAP net income d

  21. Slide 21: A unique story in biotech with significant revenue growth and profitability

    21 A unique story in biotech with significant revenue growth and profitability Two Approved Therapies One Late Stage Phase 3 Program Surpassing $1B in Total Sales in 2028 Double-digit Revenue Growth Self-Sustainable Company and Growing Free Cash Flow A Rare Company Leverageable Rare Disease Infrastr

  22. Slide 22: Appendix

    Amicus Therapeutics Appendix

  23. Slide 23: Reconciliation of Non-GAAP Financial Measures

    23 Reconciliation of Non-GAAP Financial Measures

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures (Cont'd)

    24 Reconciliation of Non-GAAP Financial Measures (Cont’d)

  25. Slide 25: Exchange Rates

    25 Exchange Rates Currency Average Rates FX Rates Q3 2024 Q3 2025 Variance USD/EUR 1.099 1.169 6.4% USD/GBP 1.301 1.349 3.7% USD/JPY 0.007 0.007 0.9%

  26. Slide 26: Rare Disease Pipeline

    26 Rare Disease Pipeline 1Exclusive rights to commercialize in the United States INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FABRY DISEASE Galafold® (migalastat) Fabry Genetic Medicines POMPE DISEASE Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Pompe Gen

Amicus Therapeutics — Q3 2025 Earnings Presentation on 6ix